Barinthus Biotherapeutics Plc.
Research Barinthus Biotherapeutics Plc. (BRNS) on Bullrun: market cap USD 26.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBRNS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 26.96M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 10.58M
- Free cash flow-USD 8.09M
Valuation Snapshot
latest market cap is USD 26.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 66.43M | -USD 48.02M | n/a | -1.64 | USD 70.46M | USD 11.28M | USD 74.21M |
| FY2024 | USD 14.97M | -USD 61.07M | -USD 29.83M | n/a | -1.55 | USD 110.66M | USD 12.01M | USD 130.03M |
| FY2023 | USD 802.00K | -USD 73.35M | -USD 56.34M | n/a | -1.91 | USD 142.09M | USD 12.98M | USD 186.78M |
| FY2022 | USD 44.70M | USD 5.34M | -USD 20.57M | n/a | 0.14 | USD 194.39M | n/a | USD 242.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 26.96M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 28.59M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 48.68M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 142.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 87.65M | 4.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 413.17M | n/a | n/a | n/a |
About Barinthus Biotherapeutics Plc.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Barinthus Biotherapeutics Plc.'s market cap?
Barinthus Biotherapeutics Plc.'s market capitalization is USD 26.96M.
What does Barinthus Biotherapeutics Plc. do?
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection.